FORMULATION AND EVALUATION OF SOLID LIPID NANOPARTICLES CONTAINING CNS ACTING DRUG

Abstract

Zolmitriptan (ZMT) is a second generation triptan prescribed for patients with migraine attacks, with or without aura and cluster headaches. When compared to traditional Zolmitriptan tablets, intranasal administration of the solid lipid nanostructure of the drug achieved a drug targeting potential of around 90% through the olfactory route, which travels from the nasal cavity to brain tissue. Due to their small particle size, they were able to pass through the narrow hole in the olfactory neurons and enter the brain through several endo-cystic channels that are found in the membranes that cover the nasal tissue. Solid lipid nanoparticles (SLNs) of Zolmitriptan were developed by solvent diffusion evaporation method. Prepared SLNs were characterized by In-vitro drug release, Transmission Electron Microscopy (TEM). To achieve our goal, six formulations (F1 to F6) of SLNs were prepared and optimized. Formulation F6 was selected as optimized formulation and was evaluated for the independent parameters. Optimized formulation showed particle size 249.5±8.7 nm, zeta potential -14.5±1.33mV, Entrapment efficiency (EE) 83.48±4.12. The drug release data suggested that the release of the drug is sustained.